Homepage - Well Referenced

Latest Articles

Association of Wearable Device-Measured Vigorous Intermittent Lifestyle Physical Activity with Mortality

This prospective cohort study analyzed data from 25,241 non-exercising adults (mean age 61.8 years) in the UK Biobank to assess the impact of vigorous intermittent lifestyle physical activity (VILPA) on mortality. VILPA, characterized by brief bouts (1–2 minutes) of vigorous activity during daily life, was measured using wearable accelerometers. Over

June 26, 2025 No Comments

Can a bout of exercise harm the human heart?

This commentary discusses a study by Stewart et al. (2016) that examined the effects of acute endurance exercise on cardiac function in recreationally active men. Participants performed two cycling trials: 90 minutes at heavy intensity and 120 minutes at moderate intensity. Findings indicated transient reductions in left and right ventricular

June 26, 2025 No Comments

Compact Arterial Monitoring Device Use in Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA): A Simple Validation Study in Swine

This 2024 study evaluated the accuracy of a compact, disposable pressure monitoring device (Compass™) used during partial REBOA procedures in a swine model. Four Yorkshire pigs underwent induced hemorrhagic shock followed by REBOA with the Compass™ transducer. Mean arterial pressures recorded by the device were compared to standard arterial line

June 26, 2025 No Comments

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

This 2022 extension of the STEP 1 trial assessed the effects of discontinuing semaglutide 2.4 mg weekly in adults with obesity. After 68 weeks of treatment, participants had lost an average of 17.3% of their body weight. One year post-withdrawal, they regained approximately two-thirds of this weight loss, resulting in

June 26, 2025 No Comments

Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial

This 2024 secondary analysis of a randomized clinical trial examined the effects of exercise, GLP-1 receptor agonist (liraglutide) treatment, and their combination on bone health in adults with obesity. After an initial 8-week low-calorie diet, 195 participants were randomized into four groups: exercise alone, liraglutide alone, combination of both, or

June 26, 2025 No Comments

Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database

This 2025 study conducted a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) to identify drugs associated with noninfectious myocarditis. Analyzing data from 2004 to 2024, the researchers found 10,763 reports of noninfectious myocarditis. The top five drugs with the highest reporting odds ratios (RORs) were phendimetrazine tartrate

June 26, 2025 No Comments

Diet: A Source of Endocrine Disruptors

This 2020 review examines how common dietary sources contribute to human exposure to endocrine-disrupting chemicals (EDCs). It highlights that food is a significant route of EDC exposure, with substances like bisphenol A (BPA), phthalates, and persistent organic pollutants (POPs) present in various food items. These chemicals can interfere with hormonal

Exposures, Mechanisms, and Impacts of Endocrine-Active Flame Retardants

This 2014 review examines the endocrine and neurodevelopmental effects of flame retardants, focusing on tris(1,3-dichloro-isopropyl) phosphate (TDCPP), Firemaster® 550 (FM550), and polybrominated diphenyl ethers (PBDEs). These chemicals, commonly used in consumer products like polyurethane foam, have led to widespread indoor exposure. PBDEs and their metabolites primarily disrupt thyroid function due

Sauna as a valuable clinical tool for cardiovascular, autoimmune, toxicant-induced and other chronic health problems

This 2011 review by Walter J. Crinnion explores the therapeutic benefits of sauna therapy across various chronic health conditions. It highlights evidence supporting sauna use in cardiovascular diseases such as hypertension, congestive heart failure, and post-myocardial infarction care. Additionally, the review discusses benefits for individuals with chronic obstructive pulmonary disease

Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy

This 2013 clinical study evaluated the safety and efficacy of human umbilical cord mesenchymal stem cells (UC-MSCs) in treating active rheumatoid arthritis (RA) unresponsive to conventional therapies. Involving 172 patients, the study compared outcomes between those receiving disease-modifying anti-rheumatic drugs (DMARDs) plus UC-MSCs and those receiving DMARDs alone. The UC-MSC

Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study

This 2014 multicenter clinical trial assessed the safety and efficacy of allogeneic umbilical cord mesenchymal stem cell transplantation (UC-MSCT) in 40 patients with active and refractory systemic lupus erythematosus (SLE). Patients received intravenous infusions of UC-MSCs on days 0 and 7. The treatment was well tolerated, with no transplantation-related adverse

Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn’s Disease: A Randomized Controlled Clinical Trial

This 2018 randomized controlled trial assessed the safety and efficacy of umbilical cord-derived mesenchymal stem cells (UC-MSCs) in patients with moderate to severe Crohn's disease (CD) unresponsive to long-term steroid therapy. Eighty-two patients were enrolled, with 41 receiving four weekly intravenous infusions of 1×10⁶ UC-MSCs/kg. After 12 months, the UC-MSC

The Current Status of Stem-Cell Therapy in Erectile Dysfunction: A Review

This 2016 review by Reed-Maldonado and Lue examines the application of stem cell (SC) therapy for erectile dysfunction (ED). The authors discuss various types of stem cells, including adipose-derived, bone marrow-derived, and umbilical cord-derived stem cells, and their potential mechanisms in treating ED. The review highlights four clinical trials where

Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial

This 2021 randomized controlled trial evaluated the long-term safety and efficacy of umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy in patients with hepatitis B virus (HBV)-related decompensated liver cirrhosis (DLC). A total of 250 patients were randomized to receive either standard care or standard care plus UC-MSC infusions at weeks

Autologous Infusion of Bone Marrow and Mesenchymal Stromal Cells in Patients with Chronic Obstructive Pulmonary Disease: Phase I Randomized Clinical Trial

This Phase I randomized, open-label clinical trial evaluated the safety and preliminary efficacy of autologous bone marrow mononuclear cells (BMMC), adipose-derived mesenchymal stromal cells (ADSC), and their co-infusion in 20 patients with moderate-to-severe COPD. Participants were divided into four groups: control (standard treatment), BMMC, ADSC, and co-infusion (BMMC + ADSC).